Summary As Current Opinion, this monograph seeks to summarize, and provoke, new
EPO/EPOR action concepts. Specific problems addressed include: beyond (and before) …

While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in
cancer patients, concerns about its adverse effects on patient survival have emerged. A lack …

BACKGROUND AND OBJECTIVE: To determine the effects of intravitreal injections of
erythropoietin in eyes with severe, chronic diabetic macular edema, 5 eyes of 5 patients …

Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical
conditions including cancer. Data from several clinical trials suggest significant adverse …

Background The association between secondhand smoke (SHS) exposure and bladder
cancer is inconclusive. Epigenetic alterations in bladder tumors have been linked to primary …

Although surgery remains the mainstay of cancer care, the advent of multidisciplinary
approaches and the use of multiple therapeutic modalities has increased treatment …

The glycoprotein hormone erythropoietin (EPO) is a key regulator in the production of red
blood cells. EPO is produced mainly in the embryonic liver and kidney of adults. Other …

Non-small-cell lung cancer (NSCLC) is the predominant type of lung cancer in the world.
Lung adenocarcinoma (LADC) and lung squamous cell carcinoma (LSCC) are subtypes of …

Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia.
Recent preclinical studies and clinical trials, however, have raised concerns about the …

Background Numerous efficacious chemotherapy regimens may cause thrombocytopenia.
Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel …